nach oben

Journal of Neuro-Oncology

Erschienen in:

01.08.2012 | Topic Review

Patients with brain tumor-related epilepsy

verfasst von: Marta Maschio, Loredana Dinapoli

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Patients with brain tumor-related epilepsy (BTRE) present a complex therapeutic profile and require a unique and multidisciplinary approach. They, in fact, must face two different pathologies at the same time, brain tumor and epilepsy. Therefore, it is necessary to develop a customized treatment plan for each individual with BTRE. This requires a vision of patient management concerned not only with medical therapies related to the oncological disease and to the correct choice of antiepileptic therapies but also with emotional and psychological support for the individual and his/her family. The choice of antiepileptic drugs is challenging for these patients because BTRE is often drug-resistant, has a strong impact on the quality of life, and weighs heavily on public health expenditures. In brain tumor patients, the presence of epilepsy is considered the most important risk factor for long-term disability. The problem of the proper administration of medications and their potential side effects is of great importance, because good seizure control also has a significant impact on the patient’s psychological and relational sphere.

Hildebrand J (2004) Management of epileptic seizures. Curr Opin Oncol 16:314–317PubMedCrossRef

Werner MH, Phuphanich S, Lyman GH (1995) The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer 76:1634–1642PubMedCrossRef

Rossetti AO, Stupp R (2010) Epilepsy in brain tumor patients. Curr Opin Neurol 23:603–609PubMedCrossRef

Singh G, Rees JH, Sander JW (2007) Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 78:342–349PubMedCrossRef

Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 54:1886–1893PubMedCrossRef

Hildebrand J, Lecaille C, Perennes J, Delattre JY (2005) Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65:212–215PubMedCrossRef

Wen PY, Marks PW (2002) Medical management of patients with brain tumors. Curr Opin Oncol 14:299–307PubMedCrossRef

Telfeian AE, Philips MF, Crino PB, Judy KD (2001) Postoperative epilepsy in patients undergoing craniotomy for glioblastoma multiforme. J Exp Clin Cancer Res 20:5–10PubMed

Luyken C, Blümcke I, Fimmers R et al (2003) The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 44:822–830PubMedCrossRef

10.

Vecht CJ, Wilms EB (2010) Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 10:663–669PubMedCrossRef

11.

DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123PubMedCrossRef

12.

Kargiotis O, Markoula S, Kyritsis AP (2011) Epilepsy in the cancer patient. Cancer Chemother Pharmacol 67:489–501PubMedCrossRef

13.

Maschio M, Dinapoli L, Sperati F et al (2010) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 104:205–214PubMedCrossRef

14.

Schaller B, Ruegg SJ (2003) Brain tumor and seizures: pathophysiology and its implications for treatment revised. Epilepsia 44:1223–1232PubMedCrossRef

15.

Whittle IR, Beaumont A (1995) Seizures in patients with supratentorial oligodendroglial tumors: clinicopathological features and management considerations. Acta Neurochir 135:19–24CrossRef

16.

Kwan P, Arzimanoglou A, Berg AT et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077PubMedCrossRef

17.

Jaeckle KA, Ballman K, Furth A, Buckner JC (2009) Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207–1213PubMedCrossRef

18.

Patsalos PN, Froscher W, Pisani F, van Rijn C (2002) The importance of drugs interactions in epilepsy therapy. Epilepsia 43:365–385PubMedCrossRef

19.

Patsalos PN, Perucca E (2003) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2:347–356PubMedCrossRef

20.

Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404–409PubMedCrossRef

21.

Löscher W (2005) How to explain multidrug resistance in epilepsy? Epilepsy Curr 5:107–112PubMedCrossRef

22.

Taillibert S, Laigle-Donadey F, Sanson M (2004) Palliative care in patients with primary brain tumors. Curr Opin Oncol 16:587–592PubMedCrossRef

23.

Klein M, Engelberts NHJ, van der Ploeg HM et al (2003) Epilepsy in lowgrade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54:514–520PubMedCrossRef

24.

Maschio M, Dinapoli L, Gomellini S et al (2010) Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol 98:109–116PubMedCrossRef

25.

Maschio M, Dinapoli L, Saveriano F et al (2009) Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. Acta Neurol Scand 120:210–212PubMedCrossRef

26.

Maschio M, Albani F, Baruzzi A et al (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80:97–100PubMedCrossRef

27.

Novy J, Stupp R, Rossetti AO (2009) Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 111:171–173PubMedCrossRef

28.

Maschio M, Dinapoli L, Mingoia M et al (2011) Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 258:2100–2104PubMedCrossRef

29.

Maschio M, Dinapoli L, Vidiri A et al (2009) The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 28:60PubMedCrossRef

30.

Beghi E (2004) Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 3:321–618CrossRef

31.

French JA, Kanner AM, Bautista J et al (2004) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology 62:1261–1273PubMedCrossRef

32.

Kwan P, Brodie MJ (2004) Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45:1141–1149PubMedCrossRef

33.

Aguiar D, Pazo R, Duran I et al (2004) Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 66:345–350PubMedCrossRef

34.

Bourg V, Lebrun C, Chichmanian RM et al (2001) Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 12:217–219PubMedCrossRef

35.

Wellington K, Goa KL (2001) Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 15:137–163PubMedCrossRef

36.

Singh BK, White-Scott S (2002) Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 11:47–50PubMedCrossRef

37.

Salinsky MC, Storzbach D, Spencer DC et al (2005) Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64:792–798PubMedCrossRef

38.

Kilpatrick ES, Forrest G, Brodie MJ (1996) Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 37:534–538PubMedCrossRef

39.

Sander JW, Hart YM, Trimble MR, Shorvon SD (1991) Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 54:435–439PubMedCrossRef

40.

Dichter MA, Brodie MJ (1996) New antiepileptic drugs. N Engl J Med 334:1583–1590PubMedCrossRef

41.

Leppik IE (2002) Three new drugs for epilepsy: levetiracetam, oxcarbazepine and zonisamide. J Child Neurol 17(Suppl 1):S53–S57PubMedCrossRef

42.

Sheth RD (2004) Bone health in epilepsy. Lancet Neurol 3:516PubMedCrossRef

43.

Maschio M, Dinapoli L, Zarabla A et al (2008) Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 86:61–70PubMedCrossRef

44.

Striano S, Striano P, Boccella P et al (2002) Tiagabine in glial tumors. Epilepsy Res 49:81–85PubMedCrossRef

45.

Khan RB, Hunt DL, Thompson SJ (2004) Gabapentin to control seizures in children undergoing cancer treatment. J Child Neurol 19:97–101PubMed

46.

Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:99–102PubMedCrossRef

47.

Maschio M, Albani F, Jandolo B et al (2008) Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. J Neurooncol 90:217–221PubMedCrossRef

48.

Dinapoli L, Maschio M, Jandolo B et al (2009) Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci 30:353–359

49.

Maschio M, Dinapoli L, Vidiri A, Muti P (2010) Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy. J Neurol 157:1939–1940CrossRef

50.

Salinsky MC, Storzbach D, Spencer DC et al (2005) Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64:792–798PubMedCrossRef

51.

Sabers A, Møller A, Dam M et al (1995) Cognitive functions and anticonvulsivant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 92:19–27PubMedCrossRef

52.

Bosma I, Vos MJ, Heimans JJ, Taphoorn MJB et al (2007) The course of neurocognitive functioning in high grade glioma patients. Neurooncol 9:53–62

53.

Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3:159–168PubMedCrossRef

54.

Krychman ML, Amsterdam A, Carter J, Castiel M, DeAngelis L (2004) Brain cancer and sexual health: a case report. Palliat Support Care 2:315–318PubMedCrossRef

55.

Smaldone M, Sukkarieh T, Reda A, Khan A (2004) Epilepsy and erectile dysfunction: a review. Seizure 13:453–459PubMedCrossRef

56.

Holtkamp M, Weissinger F, Meierkord H (2005) Erectile dysfunction with topiramate. Epilepsia 46:166–167PubMedCrossRef

57.

Maschio M, Saveriano F, Dinapoli L, Jandolo B (2011) Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. J Sex Med 8:3515–3517. doi:10.1111/j.1743-6109.2009.01373.x PubMedCrossRef

58.

Anderson GD (2004) Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 63(4):S3–S8PubMedCrossRef

59.

Yap KY, Chui WK, Chan A (2008) Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 30:1385–1407PubMedCrossRef

60.

Drappatz J, Schiff D, Kesari S et al (2007) Medical management of brain tumor patients. Neurol Clin 25:1035–1071PubMedCrossRef

61.

Rudà R, Trevisan E, Soffietti R (2010) Epilepsy and brain tumors. Curr Opin Oncol 22:611–620PubMedCrossRef

62.

Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E et al (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 31(6):21

63.

Maschio M, Dinapoli L, Zarabla A, Jandolo B (2006) Issues related to the pharmacological management of patients with brain tumours and epilepsy. Funct Neurol 21:15–19PubMed

Titel: Patients with brain tumor-related epilepsy
verfasst von: Marta Maschio
Loredana Dinapoli
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0867-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Patients with brain tumor-related epilepsy

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy

Multifocal CNS infiltration of chronic lymphocytic leukemia in the form of small-cell solid metastatic lesions

Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series

Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms

Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines

Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie